Aug 9 (Reuters) - Pharming Group NV :
* Announces acquisition of all North American commercialisation rights to Ruconest from Valeant
* $125 million deal value, with an upfront fee for Valeant of US$60 million, and self-funding sales milestone payments up to a further US$65 million in total
* Funding through a combination of straight debt and new equity capital of between US$ 80-100 million Source text for Eikon: Further company coverage: (Gdynia Newsroom)
Our Standards: The Thomson Reuters Trust Principles.